Attovia Therapeutics (NASDAQ:ATTO) Price Target Raised to $40.00

Attovia Therapeutics (NASDAQ:ATTO) had its target price increased by Morgan Stanley from $39.00 to $40.00 in a report published on Tuesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Other analysts have also issued reports about the company. Leerink Partners initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 price target on the stock. Citigroup assumed coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Research raised Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Lifesci Capital started coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Royal Bank Of Canada started coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set an “outperform” rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Attovia Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Attovia Therapeutics Stock Performance

ATTO stock opened at $15.81 on Tuesday. Attovia Therapeutics has a 12-month low of $12.94 and a 12-month high of $28.00. The business has a 50-day moving average price of $17.71.

Attovia Therapeutics (NASDAQ:ATTO) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). During the same period in the prior year, the firm posted ($3.44) earnings per share. Attovia Therapeutics’s revenue for the quarter was down 100.0% on a year-over-year basis. As a group, analysts expect that Attovia Therapeutics will post -4.19 earnings per share for the current year.

About Attovia Therapeutics

Attovia Therapeutics is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.